| Original language | English |
|---|---|
| Pages (from-to) | 384-391 |
| Number of pages | 8 |
| Journal | Vaccine |
| Volume | 37 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 7 Jan 2019 |
Bibliographical note
Funding Information:The authors are grateful for the support and helpful comments provided by Guillaume Moulis, Silvia Pessah-Eljay, Elizabeth Jamme, Robert Pless, the Brighton Collaboration Steering Committee (Jim Buttery, Barbara Law, Kathryn Edwards, Michael Gold, Miriam Sturkenboom, Steven Black, Hector Izurieta, Egeruan Babatunde Imoukhuede, Heidi Larson, Daniel Salmon) and comments received in the frame of the reference group review by: Graciela Alarcon, David Nalin, Sadhu Panda, Dinesh Kumar, Nisha Kesharybhatta, Reinaldo de Menezes Martins, Rosemary Aaron as well as other experts consulted as part of the process. We also thank the Brighton Collaboration management team, particularly, Jorgen Bauwens, Simone Casagrande, Viviane Seeger for administrative and technical support. (http://www.cioms.ch/frame_current_programme.htm) for the review of, constructive comments on, and endorsement of this document. The findings, opinions and assertions contained in this consensus document are those of the individual scientific professional members of the working group. They do not necessarily represent the official positions of each participant's organisation (e.g., government, university, or corporation).
Keywords
- Adverse drug related side effects and adverse reactions (MeSH)
- Adverse event
- Arthritis (MeSH)
- Aseptic arthritis
- Case definition
- Guidelines as topic (MesH)
- Immunisation (MeSH)
- Vaccine (MeSH)
